miércoles, 28 de febrero de 2018

Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. - PubMed - NCBI

Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. - PubMed - NCBI



 2017 Mar 14;116(6):717-725. doi: 10.1038/bjc.2017.27. Epub 2017 Feb 14.

Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer.

Pruitt SL1,2Laccetti AL3Xuan L1Halm EA1,2,3Gerber DE1,2,3.

Abstract

BACKGROUND:

Early-stage lung cancer represents a key focus of numerous multicenter clinical trials, but common exclusion criteria such as a prior cancer diagnosis may limit enrollment. We examined the prevalence and prognostic impact of a prior cancer diagnosis among patients with early-stage lung cancer.

METHODS:

We identified patients>65 years of age with early-stage lung cancer diagnosed 1996-2009 in the Surveillance, Epidemiology, and End Results-Medicare linked database. Prior cancers were characterized by type, stage, and timing with respect to the lung cancer diagnosis. All-cause and lung cancer specific-survival rates were compared between patients with and without prior cancer using Cox regression analyses and propensity scores.

RESULTS:

Among 42,910 patients with early-stage lung cancer, one-fifth (21%) had a prior cancer. The most common prior cancers were prostate (21%), breast (18%), gastrointestinal (17%), and other genitourinary (15%). Most prior cancers were localized, and 61% were diagnosed within 5 years of the lung cancer diagnosis. There was no difference in all-cause survival between patients with and without prior cancer (hazard ratio [HR] 1.01; P=0.52). Lung cancer specific survival was improved among patients with prior cancer (HR 0.79; P<0.001).

CONCLUSIONS:

A prior cancer history may exclude a substantial proportion of patients with early-stage lung cancer from enrollment in clinical trials. Without adverse effect on clinical outcomes, inclusion of patients age >65 years with prior cancer in clinical trials should be considered to improve study accrual, completion rates, and generalizability.

PMID:
 
28196065
 
PMCID:
 
PMC5355931
 [Available on 2018-03-14]
 
DOI:
 
10.1038/bjc.2017.27

[Indexed for MEDLINE]

No hay comentarios: